KRON Kronos Bio Inc
Price (delayed)
$0.836
Market cap
$50.97M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.43
Enterprise value
-$10.73M
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated
Highlights
The company's revenue has surged by 57% YoY
Kronos Bio's gross profit has soared by 57% YoY
Kronos Bio's quick ratio has decreased by 9% from the previous quarter but it has increased by 6% YoY
The equity has declined by 45% year-on-year and by 21% since the previous quarter
Key stats
What are the main financial stats of KRON
Market
Valuations
Earnings
Shares outstanding
60.97M
Market cap
$50.97M
Enterprise value
-$10.73M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.58
Price to sales (P/S)
5.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.09
Revenue
$9.85M
Gross profit
$9.85M
Operating income
-$92.89M
Net income
-$86.08M
EBIT
-$86.08M
EBITDA
-$84.36M
Free cash flow
-$65.44M
Per share
Balance sheet
Liquidity
EPS
-$1.43
EPS diluted
-$1.43
Free cash flow per share
-$1.09
Book value per share
$1.45
Revenue per share
$0.16
TBVPS
$2.07
Total assets
$124.36M
Total liabilities
$36.78M
Debt
$24.9M
Equity
$87.58M
Working capital
$99.95M
Debt to equity
0.28
Current ratio
7.54
Quick ratio
7.49
Net debt/EBITDA
0.73
Margins
Efficiency
Dividend
EBITDA margin
-856.7%
Gross margin
100%
Net margin
-874.1%
Operating margin
-943.2%
Return on assets
-55.4%
Return on equity
-75%
Return on invested capital
-91.4%
Return on capital employed
-78.9%
Return on sales
-874.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KRON stock price
How has the Kronos Bio stock price performed over time
Intraday
3.47%
1 week
-3.11%
1 month
-14.69%
1 year
-34.17%
YTD
-12%
QTD
1.33%
Financial performance
How have Kronos Bio's revenue and profit performed over time
Revenue
$9.85M
Gross profit
$9.85M
Operating income
-$92.89M
Net income
-$86.08M
Gross margin
100%
Net margin
-874.1%
The company's revenue has surged by 57% YoY
Kronos Bio's gross profit has soared by 57% YoY
The operating margin has soared by 51% year-on-year
The net margin has soared by 51% YoY
Growth
What is Kronos Bio's growth rate over time
Valuation
What is Kronos Bio stock price valuation
P/E
N/A
P/B
0.58
P/S
5.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.09
Kronos Bio's EPS has increased by 27% YoY
KRON's P/B is 57% below its 5-year quarterly average of 1.3 and 7% below its last 4 quarters average of 0.6
The equity has declined by 45% year-on-year and by 21% since the previous quarter
The company's revenue has surged by 57% YoY
KRON's P/S is 36% below its last 4 quarters average of 7.7
Efficiency
How efficient is Kronos Bio business performance
The company's return on invested capital has shrunk by 59% YoY and by 28% QoQ
Kronos Bio's return on sales has surged by 51% YoY
The ROE fell by 28% YoY and by 16% QoQ
Kronos Bio's ROA has decreased by 23% YoY and by 15% from the previous quarter
Dividends
What is KRON's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KRON.
Financial health
How did Kronos Bio financials performed over time
The total assets has declined by 42% year-on-year and by 17% since the previous quarter
The total liabilities is down by 32% year-on-year and by 5% since the previous quarter
The debt is 72% lower than the equity
Kronos Bio's debt to equity has soared by 56% YoY and by 22% from the previous quarter
The equity has declined by 45% year-on-year and by 21% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.